Innovation

A Polycistronic Vector for Human iPS Cell Production

UAB Research Foundation
posted on 12/19/2011

Since 2006, many laboratories have reported successes in deriving induced pluripotent stem cells (iPS) from somatic cells. However, in most of these cases, the methods described were unable to avoid a stable integration of the reprogramming vector that could lead to potential activation or inactivation of endogenous genes. Researchers at The University of Alabama at Birmingham (UAB) have created a reprogramming lentiviral vector that can transduce adult dermal fibroblasts into iPS cell and later be removed.

Suggested Uses

Stem Cell Production

Advantages

    Allows for reprogramming of adult dermal fibroblasts which are readily accessible by simple skin biopsies
    Provides a reliable method of reprogramming somatic cells utilizing a single, self-inactivating, polycistronic lentiviral vector
    Reprogramming sequence can easily be deleted from the iPS cell genome preventing unwanted inactivation or activation of endogenous genes
    Provides the foundation for correcting hereditary disorders by reprogramming the generated iPS cells with the corrected gene

Innovation Details
 

Detailed Description

UAB researchers have created a single, polycistronic lentiviral vector encoding the reprogramming vectors Oct4, Sox2, and Klf4 with porcine teschovirus-1 2A sequence inserted between these factors. This polycistron was cloned downstream of an elongation factor 1α promoter in a self-inactivating lentiviral vector containing a loxP site. Using this vector, adult skin fibroblasts can be transduced into iPS cells capable of forming tissue derived from all three germ layer cell types. Expression of Cre recombinase in these iPS cells resulted in the deletion of the lentiviral vector with the exception of a small remnant piece that did not interrupt coding sequence or regulatory elements. Results of in vitro and in vivo studies show that this vector can safely and effectively reprogram adult skin fibroblasts into iPS cells to correct a hereditary disorder by gene replacement therapy.

File Number: U2008-0081 

Disease: Blood and Lymphatic System

Other Information:

  • MANAGING LICENSING ASSOCIATE
  • DEBORAH J. BIDANSET, PH.D., MBA
  • debbie@uab.edu (205) 975-6851
  • IP PROTECTION
  • U.S. Patent Application Serial No. 13/480,753, PCT filed December 17, 2009.
  • PRINCIPAL INVESTIGATOR
  • Tim Townes, Ph.D., Department of Biochemistry and Molecular Genetics, UAB.

  • IP Protection

    Patent Number(s): 13/480753

    License Online

    This innovation currently is not available for online licensing. Please contact Deborah Powe at UAB Research Foundation for more information.

    Request more info via email request more info
    People

    Case Manager:

    Deborah Powe Deborah Powe

    Innovations (46)


    Download Technology Brief (PDF)


    Followed By

    Follow this innovation



    No one is following this innovation.

    Organization
    Profile
    Related Tags

    Find more innovations


    February 11, 2009

    12,878 members 17,311 innovations 176 organizations

    Browse

    Alan Thomas, Director, UChicagoTech

    "The iBridge Network has opened up new avenues for innovations at UChicagoTech. Relationships between researchers from other universities or industry can be built and strengthened, while investors can find new technologies to advance. "  read more...